Abstract Library

#4608 A complex and rare association of neuroendocrine and endocrine neoplasms: A case report

Introduction: Neuroendocrine tumours (NETs) are sporadic or genetically inherited heterogenous neoplasms affecting multiple sites.

Conference:

Presenting Author: Cerroni L

Authors: Cerroni L, Filice A, Feola T, Sesti F, Vincenzi L,

Keywords: cushing disease, atypical carcinoid, ileal net, genetics,

#4539 Single-nucleus profiling of the tumour microenvironment in SI-NET patients

Introduction: Small intestinal neuroendocrine tumours (SI-NETs) are frequently present as multiple synchronous primary tumours in the small bowel. They are thought to arise from enterochromaffin (EC) cells in the gut, which account for less than 1% of the intestinal epithelium. Previously reported lack of shared somatic driver alterations in SI-NETs suggests that other, non-genetic mechanisms are likely involved in their tumorigenesis.

Conference:

Presenting Author: Mäkinen N

Authors: Mäkinen N, Kasai Y, Kim G, Thirlwell C, Nakakura E,

Keywords: small intestinal NET, tumour microenvironment, single-nucleus sequencing,

#3805 Transcriptomic analyses of multifocal ileal neuroendocrine tumors

Introduction: Small intestinal neuroendocrine tumors are mostly located in the distal ileum with a high incidence of multiple synchronous primary tumors. To date, loss of heterozygosity (LOH) at chr18 has been the most frequent genomic event identified, occurring in ~60% of tumors. Recently, we showed that synchronous primary tumors from the same ileal NET patient display distinct somatic mutational profiles, including distinct patterns of chr18 LOH, suggesting these tumors originate independently. Thus, new mechanistic insights into multifocal ileal NETs are urgently needed.

Conference:

Presenting Author:

Authors: Mäkinen N, Zhang Z, Munn S, Kasai Y, Kim G,

Keywords: Multifocal ileal NETs, RNA-sequencing, Gene expression,

#3290 Intratumoral serotonin might decrease the efficacy of PRRT in ileal neuroendocrine tumors

Introduction: Partial remission can be achieved by peptide receptor radionuclide therapy (PRRT) in only roughly 20% of patients with midgut neuroendocrine tumor (NET). This low remission rate can be due to the radioprotective role of stored intracytoplasmic serotonin in NET cells. If blocked, e.g. by telotristatethyl, PRRT efficacy might be increased.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Prasad V

Authors: Prasad V, Klöppel G, Lupp A, Wirtz R, Kaemmerer D,

Keywords: Ileal NET, serotonin, radioprotector, PRRT, immunohistochemistry, TPH1,

#2884 An Infectious Diseases Specialist NET Patient Looks at Management of NETs

Introduction: Medical specialties may develop practices minimally influenced by other specialties.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Schmid G,

Keywords: neuroendocrine, everolimus, somatostatin analogue, drug levels,